Curtis Hecht

Curtis Hecht has extensive work experience in the biotech and life sciences industries. Curtis is currently serving as the Chief Business Officer at Tallac Therapeutics since April 2021. Previously, they held the same position at Calithera Biosciences, Inc. from April 2014 to April 2021. Curtis also worked as a Partner in Business Development at DNA Ink, a life sciences business development and licensing firm, from 2011 to 2019. Prior to that, they were a Vice President of Business Development at inVentiv Health in 2013. From 2009 to 2011, they served as the Global Business Development/ Global Alliance Director at Genentech. Curtis also had various roles at Roche from 2002 to 2009, including Global Alliance Director, Director of Business Development & Commercial Evaluations, Product Director of Oncology Marketing, and Marketing Research Analyst. Curtis started their career in 1995 as a Medicinal & Combinatorial Chemist at Trega Biosciences and later worked in marketing at ChemNavigator.com and Pfizer Inc. in 1999 and 2001, respectively.

Curtis Hecht obtained a B.S. degree in Chemistry from California State University-Sacramento. Following this, they pursued an MBA degree with a focus on Marketing, Strategy & Finance at Carnegie Mellon University - Tepper School of Business from 2000 to 2002.